These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies]. Kimura K; Yamada K; Yoshida T Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373 [TBL] [Abstract][Full Text] [Related]
24. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Rivera G; Avery T; Roberts DW Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978 [No Abstract] [Full Text] [Related]
26. Adverse effects of aneuploidy on the outcome of remission induction therapy for acute nonlymphocytic leukaemia: analysis of types of treatment failure. Preisler HD; Reese PA; Marinello MJ; Pothier L Br J Haematol; 1983 Mar; 53(3):459-66. PubMed ID: 6824587 [TBL] [Abstract][Full Text] [Related]
27. Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia. Preisler HD; Bjornsson S; Henderson ES Cancer Treat Rep; 1977; 61(1):89-92. PubMed ID: 324625 [No Abstract] [Full Text] [Related]
28. [Results of combined chemotherapy in treatment-resistant leukaemia of adults (author's transl)]. Bruntsch U; Osieka R; GAllmeier WM; Seeber S; Schmidt CG Dtsch Med Wochenschr; 1975 Nov; 100(48):2478-82. PubMed ID: 1059536 [TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy of adult acute nonlymphoblastic leukemia. Levi JA; Vincent PC; Gunz FW Ann Intern Med; 1972 Mar; 76(3):397-403. PubMed ID: 4502024 [No Abstract] [Full Text] [Related]
30. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Melia WM; Johnson PJ; Williams R Cancer; 1983 Jan; 51(2):206-10. PubMed ID: 6295596 [TBL] [Abstract][Full Text] [Related]
31. A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. Daenen S; van Imhoff GW; de Wolf JT; Vellenga E; van den Berg-de Ruiter E; Kluin-Nelemans HC Br J Haematol; 2007 Jul; 138(2):275-7. PubMed ID: 17593034 [No Abstract] [Full Text] [Related]
35. Treatment of acute nonlymphoblastic leukemia in children with a multiple-drug protocol. Haghbin M; Murphy ML; Tan CT Cancer; 1977 Oct; 40(4):1417-21. PubMed ID: 907961 [TBL] [Abstract][Full Text] [Related]
36. Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen. Perez Manga G; Madrigal Alonso P; Alburquerque Carbuccia H Cancer Chemother Pharmacol; 1982; 7(2-3):231-3. PubMed ID: 6896298 [No Abstract] [Full Text] [Related]
37. Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia. Look AT; Dahl GV; Rivera G; Mauer AM Cancer Chemother Pharmacol; 1982; 7(2-3):161-7. PubMed ID: 6177437 [No Abstract] [Full Text] [Related]
38. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age. Bern MM; Wallach SR; Arkin CF; Lokich JJ; Huberman MS; Anderson NR; Corkery JC; Paul SD; Phillips DF; Sonneborn HA Cancer Treat Rep; 1987 Feb; 71(2):201-3. PubMed ID: 3802115 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer. Eagan RT; Ahmann DL; Bisel HF Oncology; 1976; 33(3):146-8. PubMed ID: 1012648 [TBL] [Abstract][Full Text] [Related]